fda decision tirzepatide approves new weight-loss drug Zepbound (tirzepatide) FDA sets tirzepatide compounding deadlines

It gives us pause to say for an average employer group out there if youre investing in this medication for your employees, dont expect to see a return in year one. According to Joseph Leach, M.D., Senior Vice President and Chief Medical Officer at Prime, We will need results of ongoing, multi-year studies to see if this treatment has downstream impacts on other health conditions, including cardiovascular events and diabetes development prevention, which are key benefits to weight loss management

This is not optional during aggressive weight loss

Saxagliptin: A Novel Antiparkinsonian Approach

Age-related healing decline parallels GH decline